COOKIE POLICY
We apply cookies on our website. If you are not interested in the advantages of our cookies, the “Help” function of your browser can help you configure your browser to prevent cookies or delete existing cookies. Also, you can learn how to block all new cookies on your browser and which configuration steps are required to receive a notification about new cookies.
Please see the following table for cookies that we currently use on our website:
| Name of cookie | First or third party cookie? If third party: Who is setting it? | Purpose of the cookie? | What data holds the cookie? | Is it a session or persistent cookie? | If persistent, how long is its life span? |
|---|---|---|---|---|---|
| _ga | Third party, Google Analytics | Used to distinguish users. https://developers.google.com/analytics/devguides/collection/analyticsjs/cookie-usage#gajs |
A unique, randomly generated string | Persistent | 2 years |
Tepotinib is currently approved for treating advanced or metastatic METex14 NSCLC in many countries globally, including the United States and the European Union, and is under clinical investigation in various other countries. The safety and efficacy of tepotinib must be investigated following the respective national regulations and laws. There is no guarantee that tepotinib will be approved in the sought-after indication by the health authority in your country.
©2024 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. EMD Serono is the healthcare business of Merck KGaA, Darmstadt, Germany, in the US and Canada.
Use and access of this site are subject to the terms and conditions set out in our Legal Statement and Privacy Policy.
This site is intended for US residents only.
US-TEP-00809 April 2024
US-TEP-00380 August 2021